Lykos Therapeutics is focused on advancing mental healthcare through the development of investigational psychedelics, particularly midomafetamine (MDMA) capsules, aimed at treating post-traumatic stress disorder (PTSD). The company has successfully completed two Phase 3 clinical trials, MAPP1 and MAPP2, which evaluated the efficacy and safety of MDMA-assisted therapy in combination with psychological interventions. Both studies met their primary and secondary endpoints, demonstrating the potential of MDMA as a therapeutic agent for individuals suffering from moderate to severe PTSD. Lykos is committed to further exploring the use of MDMA-assisted therapy for other mental health conditions, reflecting its dedication to addressing unmet medical needs in the field.

In addition to its clinical trials, Lykos Therapeutics has established an expanded access program authorized by the FDA, allowing patients with PTSD to access investigational MDMA-assisted therapy prior to regulatory approval. This program underscores the urgent need for effective treatments in mental health, particularly for conditions like PTSD, which significantly impact individuals' lives. Lykos also supports investigator-initiated trials to foster external research that may uncover new therapeutic opportunities. Through these initiatives, Lykos Therapeutics aims to break barriers in mental healthcare and inspire change by making innovative treatments more accessible to those in need.

United States

At Lykos Therapeutics, our mission is to transform mental healthcare. We're applying decades of evidence-based research to develop investigational psychedelics to catalyze therapeutic approaches for mental health conditions. We are relentlessly exploring and reimagining novel approaches to address unmet needs in the mental healthcare space, with an initial focus on PTSD. As a Public Benefit Company, we are focused on delivering positive impact on our people, communities and society. To learn more, visit us at www.lykospbc.com.

Lykos Therapeutics

Company Details